• Home
  • Claudia Göttlich
Claudia Göttlich

Claudia Göttlich
Charles River Discovery Research Services Germany GmbH

Dr. rer. nat. Pharmaceutical Biotechnology

About

18
Publications
4,913
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
310
Citations
Citations since 2017
7 Research Items
294 Citations
2017201820192020202120222023020406080
2017201820192020202120222023020406080
2017201820192020202120222023020406080
2017201820192020202120222023020406080

Publications

Publications (18)
Article
Epithelial-to-mesenchymal transition (EMT) is discussed to be centrally involved in invasion, stemness, and drug resistance. Experimental models to evaluate this process in its biological complexity are limited. To shed light on EMT impact and test drug response more reliably, we use a lung tumor test system based on a decellularized intestinal mat...
Conference Paper
Three-dimensional (3D) cell culture platforms are increasingly being used in cancer research and drug development. Using patient derived xenograft (PDX) as tumor cell source the clinical relevance of those platforms increases significantly. In combination with live cell imaging capabilities a powerful tool for dynamic studies of drug-cell interacti...
Article
Solid tumors impose immunological and physical barriers to the efficacy of chimeric antigen receptor (CAR) T-cell therapy that are not reflected in conventional pre-clinical testing against singularized tumor cells in two-dimensional culture. Here, we established microphysiologic three-dimensional (3D) lung and breast cancer models that resemble ar...
Article
Full-text available
Chimeric antigen receptor (CAR) engineering of T cells allows one to specifically target tumor cells via cell surface antigens. A candidate target in Ewing sarcoma is the ganglioside GD2, but heterogeneic expression limits its value. Here we report that pharmacological inhibition of Enhancer of Zeste Homolog 2 (EZH2) at doses reducing H3K27 trimeth...
Thesis
Lungenkrebs ist weltweit für die meisten krebsassoziierten Tode verantwortlich. Ursache dafür ist unter anderem, dass viele Medikamente in der klinischen Anwendung, aufgrund nicht übertragbarer Ergebnisse aus der Präklinik, scheitern. Zur Entwicklung neuer Therapiestrategien werden deshalb Modelle benötigt, welche die in vivo Situation besser wider...
Article
Full-text available
Patient‐tailored therapy based on tumor drivers is promising for lung cancer treatment. For this we combined in vitro tissue models with in silico analyses. Using individual cell lines with specific mutations we demonstrate a generic and rapid stratification pipeline for targeted tumor therapy. We improve in vitro models of tissue‐conditions by a b...
Article
Full-text available
MicroRNAs are well-known strong RNA regulators modulating whole functional units in complex signaling networks. Regarding clinical application, they have potential as biomarkers for prognosis, diagnosis, and therapy. In this review, we focus on two microRNAs centrally involved in lung cancer progression. MicroRNA-21 promotes and microRNA-34 inhibit...
Article
Full-text available
In the present study, we combined an in vitro 3D lung tumor model with an in silico model to optimize predictions of drug response based on a specific mutational background. The model is generated on a decellularized porcine scaffold that reproduces tissue-specific characteristics regarding extracellular matrix composition and architecture includin...
Article
Full-text available
Background: Current treatment in Alzheimer's disease (AD) is initiated at a stage where the brain already has irreversible structural deteriorations. Therefore, the concept of treatment prior to obvious cognitive deficits has become widely accepted, and simple biochemical tests to discriminate normal aging from prodromal or demented stages are now...
Poster
Full-text available
The potential of preclinical tumor models to predict the outcome of substances in the clinic is limited. More advanced models that include features of living tissues and parts of the microenvironment are urgently needed. At the chair of “Tissue Engineering and Regenerative Medicine” (TERM) and the Translational Center “Regenerative therapies in onc...
Article
Zielsetzung: Das Verstandnis der Signalwege von Lungentumorgeweben ist die Voraussetzung fur die Entwicklung neuer und individualisierter Behandlungsstrategien. Methode: Tumorzellen zweier Zelllinien mit unterschiedlichem EGF-Rezeptor-Mutationsstatuts (A549 & HCC827) wurden auf einer auf der dezellularisierten, biologischen Tragerstruktur SISmuc au...
Data
Supplementary Figure S2TGFβ stimulation. Dynamic model simulation of different nodes of the signaling network (Figure 4A) using SQUAD. TGFβ‐receptor stimulation (initial value of TGFβ: 1.0), results in EMT signaling (0.9, nearly maximal), the activity of several other network nodes is shown in the cell‐type specific context and activation state of...
Data
Supplementary Figure S3Gefitinib effects on HCC827 in the 3D tumor tissue model. In 3D conditions the EGFR activation is reduced and apoptosis is induced in HCC827 by gefitinib. Immunohistochemical stainings of 3D tumor tissue models show weak signals for the EGFR in A549 (A, B) with no obvious phosphorylation (E, F). In HCC827 the EGFR could be cl...
Data
Supplementary Figure S1In silico modeling of gefitinib response in A549 cells bearing a Kras mutation. Dynamic model simulation of different nodes (assuming constantly hyperactive Kras at 0.4) of the signaling network (Figure 4A) using SQUAD. (A) An activating signal of the EGFR (value: 0.3; EGF approximately 0.4, not strong, wild type) evokes a mo...
Article
Full-text available
For the development of new treatment strategies against cancer, understanding signaling networks and their changes upon drug response is a promising approach to identify new drug targets and biomarker profiles. Pre-requisites are tumor models with multiple read-out options that accurately reflect the clinical situation. Tissue engineering technolog...
Patent
Full-text available
The invention relates to the detection and diagnosis of Alzheimer's disease with the use of the oligomeric state of fragments of amyloid β as a biomarker and further concerns a novel immunochem. method, e.g. a sandwich ELISA, to det. the plasma oligomeric state of Aβ(1- 40) and Aβ(1- 42) fragments of amyloid β in biol. samples. It is shown that a d...
Patent
Full-text available
The present invention pertains to a novel method for detection of Aβ peptides, in particular in plasma, and to the use of Aβ peptides for diagnosis of Alzheimer's disease. A biol. sample is contacted with at least two different capture antibodies, the resulting immune complex with Aβ peptide is detected and then destroyed, and the captured Aβ pepti...

Network

Cited By